Developer docs
API playgroundTry for free, no card

Search company profiles

Grace Science

Full company profile

uuid00024d5

Namestring
Grace Science
Legal namestring
Grace Science, LLC
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Grace Science, LLC is a privately held clinical-stage biotechnology company founded in 2018 by Matt Wilsey and Nobel Laureate Dr. Carolyn Bertozzi to develop therapeutics based on NGLY1 biology, the product of over a decade of research initiated through the Grace Science Foundation starting in 2013. Headquartered in Menlo Park, California, the company operates with a lean team of 11–50 employees and targets both ultra-rare genetic disease (NGLY1 Deficiency) and larger indications in oncology and neurodegeneration that converge on the same NGLY1/NFE2L1 axis.

The pipeline is built around four programs: GS-100, an AAV9 single-stranded viral vector gene therapy delivering the full-length human NGLY1 protein, currently in a Phase 1/2/3 trial (NCT06199531) for NGLY1 Deficiency; GS-220 and GS-221, small molecule NGLY1 inhibitors designed to indirectly suppress the NFE2L1 transcription factor for undisclosed oncology indications; and GS-310, a small molecule program for neurodegenerative diseases such as Parkinson's disease. The underlying technology platform is anchored by more than a decade of NGLY1 pathway research, including a 2017 breakthrough linking NGLY1 to cancer and neurodegeneration, and a foundation-funded network of nearly 75 scientists across 20 medical centers in 5 countries.

Grace Science is pre-revenue and has not disclosed pricing or a commercial model. The intended revenue mechanism is eventual commercialization of ultra-rare disease gene therapies following regulatory approval, typically priced above $1 million per treatment; the addressable population for the lead indication is approximately 12 US births per year. Patient access is currently restricted to clinical trial enrollment (no expanded access program offered). The company has secured FDA Orphan Drug Designation (June 2021), IND clearance (November 2023), FDA START Pilot Program selection (June 2024), and RMAT designation (April 2026) for GS-100, and operates a strategic collaboration with Takeda. Only one funding round of $7 million (February 2017) has been disclosed, and the company faces an FDA-request bottleneck that could delay gene therapy development.

Short descriptiontext

Grace Science, LLC is a clinical-stage biotechnology company developing AAV9 gene therapy (GS-100) and small molecule therapeutics (GS-220, GS-221, GS-310) based on NGLY1 biology, targeting the ultra-rare NGLY1 Deficiency as well as oncology and neurodegenerative diseases.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMenlo Park, United States
HQ citystring
Menlo Park
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rare disease therapeutics, AAV9 gene therapy, small molecule inhibitors, oncology drug development, neurodegenerative disease research
Industry2 codes
PRIMARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Rare Disease Biopharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Gene Therapy Commercialization
TypeOne Time License
Description

Pre-revenue clinical stage biotech company developing therapies for ultra-rare diseases. Revenue generation model would be through eventual therapy commercialization following regulatory approval, likely with premium pricing typical of orphan/rare disease gene therapies.

gracescience.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Grace Science is a clinical-stage biopharmaceutical company developing therapeutics based on NGLY1 biology. Its lead asset GS-100 is an AAV9 gene therapy delivering the full-length human NGLY1 protein to treat the ultra-rare genetic disease NGLY1 Deficiency, currently in a Phase 1/2/3 clinical trial. The company is also advancing small molecule programs (GS-310 for neurodegeneration and GS-220/GS-221 for oncology) that target NGLY1 to indirectly shut down the NFE2L1 transcription factor.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Patients treated with GS-100 for at least 52 weeks demonstrated improvements in motor function including ability to sit, stand, or walk with assistance, as well as improvements in cognitive skills and caregiver interaction
Product overview1 text field

Grace Science is a biotechnology company developing a pipeline of therapeutics based on NGLY1 biology. The company's portfolio includes GS-100, an AAV9 gene therapy for NGLY1 Deficiency (the lead program currently in Phase 1/2/3 clinical trials), and multiple small molecule programs including GS-310 for neurodegenerative diseases and GS-220/GS-221 for oncology. The company leverages its deep understanding of the NGLY1 pathway to develop treatments across rare and common diseases in Oncology and Neurodegeneration. The company is agnostic to therapeutic modality, developing both gene therapies and small molecules.

Product and service4 records
1GS-100
CategoryGene therapy - rare disease
Description

An AAV9 single-stranded viral vector gene therapy that encodes the full-length human NGLY1 protein, being developed to treat NGLY1 Deficiency, an ultra-rare autosomal recessive disease that devastates the central nervous system. Patients in the ongoing Phase 1/2/3 trial (NCT06199531) treated for at least 52 weeks have demonstrated improvements in motor function (ability to sit, stand, or walk with assistance), cognitive skills, and caregiver interaction.

2GS-310
CategorySmall molecule - neurodegeneration
Description

A small molecule program for neurodegenerative diseases leveraging research showing that NGLY1 touches many of the same pathways impacted in common neurodegenerative diseases such as Parkinson's disease.

3GS-220
CategorySmall molecule - oncology
Description

A small molecule inhibitor program being developed to treat undisclosed cancers. The target of inhibition is NGLY1, which in turn shuts down NFE2L1, a critical transcription factor that is difficult to inhibit directly.

4GS-221
CategorySmall molecule - oncology
Description

A small molecule inhibitor program being developed to treat undisclosed cancers. The target of inhibition is NGLY1, which in turn shuts down NFE2L1, a critical transcription factor that is difficult to inhibit directly.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Takeda collaboration mentioned on Grace Science website as a key partnership, with video content titled 'IT TAKES ONE LITTLE SPARK' highlighting the collaboration. Nature of collaboration not detailed in available sources but represents a significant pharma partnership for a biotech of this stage.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

AAV gene therapy platform company with approved and clinical-stage assets for rare diseases; comparable in AAV vector technology and rare disease gene therapy development focus, including CNS indications similar to GS-100.

TypeDirect peer
Description

Commercial and clinical-stage rare disease company with multiple modalities including gene therapy; comparable in ultra-rare genetic disease focus, regulatory designation strategy, and platform approach across multiple rare indications.

TypeBroad incumbent
Description

Established rare-disease biotech with approved enzyme replacement and gene therapies; multiple Grace Science leaders (CSO, SAB, Senior Advisor) came directly from BioMarin's rare disease and gene therapy programs, making it the most comparable incumbent operating model.

TypeBroad incumbent
Description

Major pharmaceutical company with active gene therapy programs (including rare disease AAV-based assets from the Beam/Sangamo collaborations and prior rare disease acquisitions); comparable as a broad incumbent that competes for rare disease gene therapy assets and partnerships.

TypeBroad incumbent
Description

Global pharmaceutical company with a significant rare disease and gene therapy franchise and an active strategic collaboration with Grace Science; comparable as both a partnership counterparty and as a broader incumbent that has invested in rare disease gene therapy.

TypeDirect peer
Description

Clinical-stage gene therapy company developing AAV-based treatments with CNS-focused programs; comparable in AAV vector platform technology and neurodegenerative disease pipeline overlap with Grace Science's GS-310 program.

TypeDirect peer
Description

Clinical-stage AAV gene therapy company focused on rare and ultra-rare CNS diseases; directly comparable in CNS-targeted AAV gene therapy, ultra-rare patient population, and clinical execution profile.

TypeDirect peer
Description

Clinical-stage AAV gene therapy company developing treatments for rare genetic diseases including CNS-targeted programs; comparable in modality (AAV9-class vectors), ultra-rare indication focus, and regulatory milestones like RMAT.

TypeDirect peer
Description

Commercial-stage gene therapy company targeting ultra-rare genetic neuromuscular diseases with AAV-based modalities (Elevidys); directly comparable in regulatory pathway, patient population dynamics, and orphan pricing model for an AAV gene therapy.

TypeDirect peer
Description

Clinical-stage gene therapy company developing AAV-based treatments for rare neuromuscular genetic diseases; comparable in AAV modality, ultra-rare patient population, and clinical-stage development profile.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Grace Science

Rare Disease Biopharmaceuticalsgracescience.com

Grace Science, LLC is a clinical-stage biotechnology company developing AAV9 gene therapy (GS-100) and small molecule therapeutics (GS-220, GS-221, GS-310) based on NGLY1 biology, targeting the ultra-rare NGLY1 Deficiency as well as oncology and neurodegenerative diseases.

What Grace Science does

Grace Science, LLC is a privately held clinical-stage biotechnology company founded in 2018 by Matt Wilsey and Nobel Laureate Dr. Carolyn Bertozzi to develop therapeutics based on NGLY1 biology, the product of over a decade of research initiated through the Grace Science Foundation starting in 2013. Headquartered in Menlo Park, California, the company operates with a lean team of 11–50 employees and targets both ultra-rare genetic disease (NGLY1 Deficiency) and larger indications in oncology and neurodegeneration that converge on the same NGLY1/NFE2L1 axis.

The pipeline is built around four programs: GS-100, an AAV9 single-stranded viral vector gene therapy delivering the full-length human NGLY1 protein, currently in a Phase 1/2/3 trial (NCT06199531) for NGLY1 Deficiency; GS-220 and GS-221, small molecule NGLY1 inhibitors designed to indirectly suppress the NFE2L1 transcription factor for undisclosed oncology indications; and GS-310, a small molecule program for neurodegenerative diseases such as Parkinson's disease. The underlying technology platform is anchored by more than a decade of NGLY1 pathway research, including a 2017 breakthrough linking NGLY1 to cancer and neurodegeneration, and a foundation-funded network of nearly 75 scientists across 20 medical centers in 5 countries.

Grace Science is pre-revenue and has not disclosed pricing or a commercial model. The intended revenue mechanism is eventual commercialization of ultra-rare disease gene therapies following regulatory approval, typically priced above $1 million per treatment; the addressable population for the lead indication is approximately 12 US births per year. Patient access is currently restricted to clinical trial enrollment (no expanded access program offered). The company has secured FDA Orphan Drug Designation (June 2021), IND clearance (November 2023), FDA START Pilot Program selection (June 2024), and RMAT designation (April 2026) for GS-100, and operates a strategic collaboration with Takeda. Only one funding round of $7 million (February 2017) has been disclosed, and the company faces an FDA-request bottleneck that could delay gene therapy development.

Grace Science firmographics

Firmographics
Name
Grace Science
Legal name
Grace Science, LLC
Website
https://gracescience.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
Grace Science, LLC is a clinical-stage biotechnology company developing AAV9 gene therapy (GS-100) and small molecule therapeutics (GS-220, GS-221, GS-310) based on NGLY1 biology, targeting the ultra-rare NGLY1 Deficiency as well as oncology and neurodegenerative diseases.
Ownership category
akta.pro rank

Grace Science industry classification

Industry
Product category
Rare Disease Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Rare disease therapeutics
  • AAV9 gene therapy
  • Small molecule inhibitors
  • Oncology drug development
  • Neurodegenerative disease research

Where Grace Science is headquartered

Location

Headquarters

HQ city
Menlo Park
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Grace Science business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Gene Therapy Commercialization: Pre-revenue clinical stage biotech company developing therapies for ultra-rare diseases. Revenue generation model would be through eventual therapy commercialization following regulatory approval, likely with premium pricing typical of orphan/rare disease gene therapies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Grace Science product offering

Product offering

Core offering

Grace Science is a clinical-stage biopharmaceutical company developing therapeutics based on NGLY1 biology. Its lead asset GS-100 is an AAV9 gene therapy delivering the full-length human NGLY1 protein to treat the ultra-rare genetic disease NGLY1 Deficiency, currently in a Phase 1/2/3 clinical trial. The company is also advancing small molecule programs (GS-310 for neurodegeneration and GS-220/GS-221 for oncology) that target NGLY1 to indirectly shut down the NFE2L1 transcription factor.

Product overview

Grace Science is a biotechnology company developing a pipeline of therapeutics based on NGLY1 biology. The company's portfolio includes GS-100, an AAV9 gene therapy for NGLY1 Deficiency (the lead program currently in Phase 1/2/3 clinical trials), and multiple small molecule programs including GS-310 for neurodegenerative diseases and GS-220/GS-221 for oncology. The company leverages its deep understanding of the NGLY1 pathway to develop treatments across rare and common diseases in Oncology and Neurodegeneration. The company is agnostic to therapeutic modality, developing both gene therapies and small molecules.

Differentiator

Problem solved

Functional benefit

Products and services

  • GS-100 An AAV9 single-stranded viral vector gene therapy that encodes the full-length human NGLY1 protein, being developed to treat NGLY1 Deficiency, an ultra-rare autosomal recessive disease that devastates the central nervous system. Patients in the ongoing Phase 1/2/3 trial (NCT06199531) treated for at least 52 weeks have demonstrated improvements in motor function (ability to sit, stand, or walk with assistance), cognitive skills, and caregiver interaction.
  • GS-310 A small molecule program for neurodegenerative diseases leveraging research showing that NGLY1 touches many of the same pathways impacted in common neurodegenerative diseases such as Parkinson's disease.
  • GS-220 A small molecule inhibitor program being developed to treat undisclosed cancers. The target of inhibition is NGLY1, which in turn shuts down NFE2L1, a critical transcription factor that is difficult to inhibit directly.
  • GS-221 A small molecule inhibitor program being developed to treat undisclosed cancers. The target of inhibition is NGLY1, which in turn shuts down NFE2L1, a critical transcription factor that is difficult to inhibit directly.

Quantifiable outcome

  • Patients treated with GS-100 for at least 52 weeks demonstrated improvements in motor function including ability to sit, stand, or walk with assistance, as well as improvements in cognitive skills and caregiver interaction

Companies that use Grace Science

Customer profile

Segments3 records

Ideal customer profiles3 records

Grace Science technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Grace Science partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • TakedacoreStrategic or Co-development PartnerTakeda collaboration mentioned on Grace Science website as a key partnership, with video content titled 'IT TAKES ONE LITTLE SPARK' highlighting the collaboration. Nature of collaboration not detailed in available sources but represents a significant pharma partnership for a biotech of this stage.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Grace Science competitors and assessment

Company assessment

Direct peers

  • Regenxbio: AAV gene therapy platform company with approved and clinical-stage assets for rare diseases; comparable in AAV vector technology and rare disease gene therapy development focus, including CNS indications similar to GS-100.
  • Ultragenyx Pharmaceutical: Commercial and clinical-stage rare disease company with multiple modalities including gene therapy; comparable in ultra-rare genetic disease focus, regulatory designation strategy, and platform approach across multiple rare indications.
  • Voyager Therapeutics: Clinical-stage gene therapy company developing AAV-based treatments with CNS-focused programs; comparable in AAV vector platform technology and neurodegenerative disease pipeline overlap with Grace Science's GS-310 program.
  • Taysha Gene Therapies: Clinical-stage AAV gene therapy company focused on rare and ultra-rare CNS diseases; directly comparable in CNS-targeted AAV gene therapy, ultra-rare patient population, and clinical execution profile.
  • uniQure: Clinical-stage AAV gene therapy company developing treatments for rare genetic diseases including CNS-targeted programs; comparable in modality (AAV9-class vectors), ultra-rare indication focus, and regulatory milestones like RMAT.
  • Sarepta Therapeutics: Commercial-stage gene therapy company targeting ultra-rare genetic neuromuscular diseases with AAV-based modalities (Elevidys); directly comparable in regulatory pathway, patient population dynamics, and orphan pricing model for an AAV gene therapy.
  • Solid Biosciences: Clinical-stage gene therapy company developing AAV-based treatments for rare neuromuscular genetic diseases; comparable in AAV modality, ultra-rare patient population, and clinical-stage development profile.

Broad incumbents

  • BioMarin Pharmaceutical: Established rare-disease biotech with approved enzyme replacement and gene therapies; multiple Grace Science leaders (CSO, SAB, Senior Advisor) came directly from BioMarin's rare disease and gene therapy programs, making it the most comparable incumbent operating model.
  • Pfizer: Major pharmaceutical company with active gene therapy programs (including rare disease AAV-based assets from the Beam/Sangamo collaborations and prior rare disease acquisitions); comparable as a broad incumbent that competes for rare disease gene therapy assets and partnerships.
  • Takeda Pharmaceutical: Global pharmaceutical company with a significant rare disease and gene therapy franchise and an active strategic collaboration with Grace Science; comparable as both a partnership counterparty and as a broader incumbent that has invested in rare disease gene therapy.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Grace Science social profiles

Digital presence

Grace Science financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Grace Science leadership team

Management profile

Number of profiles

Profiles8 records

Grace Science funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Grace Science M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Grace Science

What does Grace Science do?

Grace Science is a clinical-stage biopharmaceutical company developing therapeutics based on NGLY1 biology. Its lead asset GS-100 is an AAV9 gene therapy delivering the full-length human NGLY1 protein to treat the ultra-rare genetic disease NGLY1 Deficiency, currently in a Phase 1/2/3 clinical trial. The company is also advancing small molecule programs (GS-310 for neurodegeneration and GS-220/GS-221 for oncology) that target NGLY1 to indirectly shut down the NFE2L1 transcription factor.

Is Grace Science a public or private company?

Grace Science is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Grace Science founded?

Grace Science was founded in 2013. It employs 11 to 50 people.

Where is Grace Science based?

Grace Science is headquartered in Menlo Park, United States, in the North America region.

How does Grace Science make money?

One revenue line is on record: gene Therapy Commercialization.

Who are Grace Science's main competitors?

Direct peers on record are Regenxbio, Ultragenyx Pharmaceutical, Voyager Therapeutics, Taysha Gene Therapies, uniQure, Sarepta Therapeutics and Solid Biosciences. Broad incumbents are BioMarin Pharmaceutical, Pfizer and Takeda Pharmaceutical.

Does Grace Science have an API?

No public API is recorded for Grace Science.

What industry is Grace Science in?

Grace Science's product category is Rare Disease Biopharmaceuticals. Its primary akta.pro industry code is HLAIAIAA, Genetic & Genomic Rare Disease Therapeutics, with a secondary code of HLAAACAN, Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
STATHow one father built a biotech, Grace Science, to save his daughter | STATMatt Wilsey spent a decade and $70 million building Grace Science to develop a gene therapy for his daughter Grace, who has the ultra-rare NGLY1 deficiency, and has now treated 10 patients including her in a clinical trial. The company has exhausted its funds and lacks what the FDA says it needs for approval, yet Wilsey is pressing forward with the agency as a pivotal test case for rare disease drug development. Grace's therapy caused serious adverse effects that hospitalized her, raising questions about whether the company's approach can succeed where traditional drug development pathways have failed.STATThe quest to save Grace — and clear the way for rare disease patients everywhereMatt Wilsey spent a decade and $70 million developing a gene therapy for his daughter Grace, who has NGLY1 deficiency. His company treated 10 patients, including Grace, in a clinical trial but lacks FDA approval data. He is pressing the agency anyway, setting a precedent for rare-disease treatments.RegmednetCell therapy weekly: in vivo CAR-T agreementAcuitas Therapeutics and Circio entered a technology evaluation agreement to assess whether Acuitas' lipid nanoparticle (LNP) technology can be combined with Circio's circular RNA expression platform (circVec) for novel in vivo CAR-T therapy targeting cancer and autoimmune diseases. Grace Science received RMAT designation from the FDA for its investigational gene therapy GS-100, which uses an AAV9 vector to deliver a functional version of the human NGLY1 protein for patients with NGLY1 deficiency. VectorBuilder introduced MuteFree AAV, a stable AAV vector designed to address instability in the inverted terminal repeat region that commonly compromises gene therapy manufacturing and therapeutic performance.BioSpaceU.S. FDA Grants RMAT Designation to GS-100, Grace Science’s Gene Therapy to Treat NGLY1 DeficiencyThe U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy (RMAT) designation to GS-100, an investigational AAV9 gene replacement therapy developed by Grace Science for treating NGLY1 Deficiency, an ultra-rare genetic disease with no approved therapy. Early clinical evidence from an ongoing Phase 1/2/3 trial shows patients treated with GS-100 for at least 52 weeks demonstrated improvements in motor function, including gains in the ability to sit, stand, or walk with assistance, as well as improvements in cognitive skills and caregiver interaction. The RMAT designation provides a potentially streamlined regulatory path and expedited review process for the therapy.PR NewswireAndelyn Biosciences and Grace Science, LLC Partner to Tech Transfer Phase I/II/III Manufacturing of a Suspension Process Adeno-Associated Virus (AAV) Gene Therapy for NGLY1 DeficiencyAndelyn Biosciences and Grace Science have entered a partnership to handle the tech transfer and manufacturing of GS-100, an AAV gene therapy for NGLY1 Deficiency. The collaboration aims to leverage Andelyn's late-stage manufacturing capabilities to support Grace Science's ongoing clinical trials and accelerate the therapy's availability. Grace Science has already dosed its first patient with GS-100 and plans to dose a second patient in May 2024.VenturevalkyrieNew from Tech Tonics: Matt Wilsey, Leading with and For GraceMatt Wilsey, CEO of Grace Science, is driving a company to cure NGLY1 deficiency, a genetic disorder affecting about 75 people worldwide. He expects clinical trials of the drug they developed to begin within two years. He also founded the Grace Science Foundation to raise funds for the cure.